scout
Opinion|Videos|December 8, 2023

EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME